SCHEDULE: Lombard Odier Amends Silence Therapeutics Stake
Beneficial Ownership Report
Lombard Odier Asset Management (USA) Corp reported a 4.2% beneficial ownership stake in Silence Therapeutics plc as of December 31, 2025.
Summary
- Lombard Odier Asset Management (USA) Corp filed an Amendment No. 6 to Schedule 13G regarding its beneficial ownership in Silence Therapeutics plc.
- As of December 31, 2025, Lombard Odier beneficially owned 5,935,955 Ordinary Shares of Silence Therapeutics plc.
- This ownership represents 4.2% of the total 141,701,848 Ordinary Shares outstanding as of October 30, 2025.
- The reported shares include 1,978,650 American Depositary Shares (ADSs), with each ADS convertible into three Ordinary Shares.
- Lombard Odier Asset Management (USA) Corp serves as the investment advisor for 1798 Volantis Fund Ltd, 1798 UK Small Cap Best Ideas Fund Ltd, and one or more managed accounts holding these shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral. It is a routine disclosure of an institutional investor's beneficial ownership, indicating a continued, but not significantly altered, stake below the 5% threshold.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that Schedule 13G filings provide transparency into significant institutional ownership stakes, offering insights into major investors' positions in publicly traded companies. This filing indicates Lombard Odier Asset Management's continued, albeit below 5%, interest in Silence Therapeutics plc, a common practice for institutional investors managing diversified portfolios.
Stakeholder Impact
- Provides transparency to shareholders and the market regarding a significant institutional investor's stake in Silence Therapeutics plc.
Key Dates
| Date | Description |
|---|---|
| 2025-10-30 | Date of outstanding shares calculation (141,701,848 shares) |
| 2025-11-06 | Date Silence Therapeutics plc filed Form 10-Q reporting outstanding shares |
| 2025-12-31 | Date of event requiring filing of this statement (reporting period end) |
| 2026-02-09 | Date of Schedule 13G filing signature |
Keywords
Silence Therapeutics, Lombard Odier Asset Management, Schedule 13G, Beneficial Ownership, Ordinary Shares, ADSs, Investment Adviser, G8128Y157
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.